Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VBIO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, and the auditor's report includes a going concern explanatory paragraph.
- Best Efforts Offering With No Minimum (new) — The offering is conducted on a reasonable best efforts basis with no minimum number of securities or proceeds required to close, meaning the company may raise substantially less than the estimated $13.7 million.
- Immediate Dilution (new) — New investors will experience immediate dilution of $0.02 to $0.03 per share based on the assumed offering price and net tangible book value.
- Reverse Stock Split (new) — The company plans a reverse stock split to maintain Nasdaq listing, but there is no assurance it will be approved or that the stock price will remain high enough.
Valion Bio files for up to $15M best-efforts IPO at $0.51/share plus warrants; no minimum raise
Filed July 17, 2026 · ~2 min read
Key Changes
-
high
Offering up to 29.4M shares with warrants at assumed $0.51 combined price; best-efforts, no minimum, actual proceeds may be far less.
The Offering verify on EDGAR → -
high
Company estimates $13.7M net proceeds if maximum sold; at 25% subscription, net proceeds fall to $3.1M.
Use of Proceeds verify on EDGAR → -
medium
Proceeds for working capital and general corporate purposes, including R&D and possible acquisitions; no specific allocation.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $0.02–$0.03 per share; existing holders see $0.28–$0.29 decrease in net tangible book value per share.
Dilution verify on EDGAR → -
high
Auditor's report includes going concern explanatory paragraph; company states substantial doubt about ability to continue as a going concern.
-
medium
Implied post-offering market cap $17.1M based on 33.6M shares outstanding at $0.51.
The Offering verify on EDGAR →
Summary
Valion Bio, a biopharmaceutical company focused on the TLR5 agonist Entolimod, has filed for an IPO of up to 29.4 million shares with warrants at an assumed combined price of $0.51 per share. The offering is being conducted on a best-efforts basis with no minimum, meaning the company may raise far less than the estimated $13.7 million in net proceeds.
The company intends to use the proceeds for working capital and general corporate purposes, including research and development and potential acquisitions. New investors face immediate dilution of $0.02 to $0.03 per share, and the implied post-offering market capitalization is $17.1 million. However, the filing contains several significant red flags.
The company's auditor has included a going concern explanatory paragraph, and management states there is substantial doubt about its ability to continue as a going concern. Even after this offering, the company will need substantial additional funding. The offering has no minimum, so the actual proceeds are uncertain. Additionally, the company plans a reverse stock split to maintain its Nasdaq listing, which could reduce liquidity and increase costs for odd-lot holders. Investors should carefully consider these risks. The company's future depends almost entirely on the success of Entolimod, a drug candidate licensed from Statera Biopharma. While the company highlights prior investment and FDA designations, there is no guarantee of approval or commercial success. The going concern warning and the best-efforts structure of the offering mean that the company may not have sufficient capital to advance its business plan, and the reverse stock split adds further uncertainty.
Section-by-Section Diff
The Offering · The Offering
Valion Bio plans to offer up to 29.4M shares with warrants at an assumed $0.51 combined price, with no final pricing set.
Added in current filing · verify on EDGAR →
Up to 29,411,764 shares of our common stock.
The company is offering up to 29,411,764 shares of common stock. This is a preliminary number from the S-1 filing; the final offering size may change.
Added in current filing · verify on EDGAR →
Common Warrants to purchase up to 29,411,764 shares of our common stock. Each Common Warrant will have an assumed exercise price of $0.51 per share, will be exercisable commencing on the date of issuance and will expire five years from the date of issuance.
Each share is sold together with a warrant to buy one additional share at $0.51, exercisable for five years. The exercise price is assumed and may change.
Added in current filing · verify on EDGAR →
We are also offering to those purchasers, if any, whose purchase of common stock in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, Pre-Funded Warrants in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock.
Investors who would exceed 4.99% or 9.99% ownership can buy pre-funded warrants instead of common stock. These warrants have a nominal exercise price of $0.0001 and reduce the number of common shares offered one-for-one.
Added in current filing · verify on EDGAR →
at an assumed combined public offering price of $0.51 per share and Common Warrant (based upon the last reported sale price of our common stock on The Nasdaq Capital Market on July 13, 2026).
The $0.51 price is an assumption based on the last reported sale price on July 13, 2026. The actual offering price has not been determined and may differ.
Added in current filing · verify on EDGAR →
Up to 33,563,023 shares of common stock.(1)
If all offered shares are sold, the company would have up to 33,563,023 shares outstanding. This is a preliminary estimate and does not include shares issuable upon exercise of warrants.
Use of Proceeds · Use of Proceeds
Valion Bio estimates $13.7M net proceeds from a best-efforts offering at $0.51/share+warrant, for working capital and general purposes.
Added in current filing · verify on EDGAR →
We estimate that the net proceeds to us from this offering will be approximately $13.7 million (assuming the issuance and sale of the maximum number of securities offered pursuant to this prospectus, there are no issuances of Pre-Funded Warrants and the Common Warrants and Placement Agent Warrants are not exercised), based on the assumed combined public offering price of $0.51 per share and Common Warrant, the last reported sale price of our Common Stock on Nasdaq on July 13, 2026, and after deducting the estimated Placement Agent fees and estimated offering expenses payable by us and excluding the proceeds, if any, from the subsequent exercise of the Pre-Funded Warrants and Common Warrants.
The company estimates net proceeds of approximately $13.7 million if the maximum number of securities is sold at the assumed combined price of $0.51 per share and Common Warrant. This is a preliminary estimate based on the last reported sale price on July 13, 2026, and is subject to change because the offering is on a best-efforts basis with no minimum.
Added in current filing · verify on EDGAR →
However, because this offering is being conducted on a reasonable best efforts basis with no minimum number of securities or amount of proceeds as a condition to closing, the actual net proceeds that we receive is not presently determinable and may be substantially less.
The offering is being conducted on a best-efforts basis with no minimum number of securities or amount of proceeds required to close. This means the company may raise significantly less than the estimated $13.7 million, and the actual amount is not determinable at this time.
Added in current filing · verify on EDGAR →
Based on the assumed combined public offering price set forth above, we estimate that our net proceeds from the sale of 75%, 50%, and 25% of the securities offered in this offering would be approximately $10.1 million, $6.6 million, and $3.1 million, respectively, after deducting the estimated Placement Agent fees and estimated offering expenses payable by us.
The company provides estimates of net proceeds if only 75%, 50%, or 25% of the securities are sold: $10.1 million, $6.6 million, and $3.1 million, respectively. These figures illustrate the potential shortfall from the maximum estimate and highlight the uncertainty of the offering.
Added in current filing · verify on EDGAR →
We intend to use the net proceeds from this offering for working capital and general corporate purposes, which may include operating expenses, research and development, and pending and future acquisitions.
The company plans to use the net proceeds for working capital and general corporate purposes, including operating expenses, research and development, and potential acquisitions. No specific amounts have been allocated to any particular use, and management retains broad discretion.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and growth of the business, and therefore, do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future.
The company has never paid cash dividends and does not anticipate paying any in the foreseeable future, as it intends to retain all funds for business development and growth. Investors should not expect dividend income from this investment.
Dilution · Dilution
Offering at $0.51/share dilutes existing holders by $0.28-$0.29/share; new investors face $0.02-$0.03/share dilution.
Added in current filing · verify on EDGAR →
After giving effect to the sale of 29,411,764 shares of our common stock (and no sale of Pre-Funded Warrants) and Common Warrants pursuant to this prospectus in the aggregate amount of $15,000,000 at an assumed combined public offering price of $0.51 per share and accompanying Common Warrant, the last reported sale price of our common stock on The Nasdaq Capital Market on July 13, 2026
The company plans to sell 29,411,764 shares plus Common Warrants for $15,000,000 at an assumed combined price of $0.51 per share. This is a preliminary assumed price based on the July 13, 2026 market price, not a final set price.
Added in current filing · verify on EDGAR →
Our net tangible book value as of March 31, 2026 was approximately $2.2 million, or approximately $0.77 per share of common stock.
Before the offering, the company's tangible assets minus liabilities were about $2.2 million, or $0.77 per share. This is the baseline against which dilution is measured.
Added in current filing · verify on EDGAR →
our net tangible book value as of March 31, 2026 would have been approximately $15.9 million, or $0.49 per share of common stock. This represents a decrease in the net tangible book value per share to our existing stockholders of approximately $0.28 per share and an immediate dilution in the net tangible book value of approximately $0.02 per share to new investors.
After the offering, net tangible book value per share drops to $0.49, a $0.28 decrease for existing stockholders. New investors buying at $0.51 per share immediately lose about $0.02 per share in book value.
Added in current filing · verify on EDGAR →
our pro forma net tangible book value as of March 31, 2026 would have been approximately $15.9 million, or $0.48 per share of common stock. This represents a decrease in net tangible book value to existing stockholders of approximately $0.29 per share of common stock and an immediate dilution in the net tangible book value of approximately $0.03 per share to new investors.
Including 1,271,402 shares issued after March 31, 2026, pro forma net tangible book value per share is $0.48, a $0.29 decrease for existing holders and $0.03 dilution for new investors. The pro forma figures are illustrative only.
Added in current filing · verify on EDGAR →
Assumed offering price per share $ 0.51 Historical net tangible book value per share as of March 31, 2026 $ 0.77 Decrease per share attributable to this offering $ (0.28 ) As adjusted net tangible book value per share as of March 31, 2026, after giving effect to this offering $ 0.49 Pro Forma net tangible book value per share as of March 31, 2026, after giving effect to this offering $ 0.48
The table summarizes the dilution: assumed offering price $0.51, historical net tangible book value $0.77, decrease of $0.28, as adjusted $0.49, and pro forma $0.48 per share.
Risk Factors · Risk Factors
Valion Bio faces substantial doubt about its ability to continue as a going concern and needs significant additional funding after this offering.
Added in current filing · verify on EDGAR →
There is substantial doubt regarding our ability to continue as a going concern. Following this offering, we will still need to raise substantial additional funding, which may not be available on acceptable terms, if at all, to be able to continue as a going concern and advance our business plan.
The company discloses substantial doubt about its ability to continue as a going concern and states that even after this offering it will need substantial additional funding. This is a critical risk that could lead to liquidation or severe operational cutbacks.
Added in current filing · verify on EDGAR →
This offering is being conducted on a reasonable best efforts basis, with no minimum amount of securities required to be sold, and we may sell fewer than all of the securities offered hereby.
The offering has no minimum amount, so the company may raise far less than the maximum. Proceeds are not determinable and could be substantially less, increasing the risk of insufficient capital.
Added in current filing · verify on EDGAR →
Based on the assumed combined public offering price of $0.51 per share and Common Warrant, the last reported sale price of our common stock on The Nasdaq Capital Market on July 13, 2026, and after deducting the estimated Placement Agent fees and estimated offering expenses payable by us, you will experience immediate dilution of $0.02 per share, representing the difference between our as adjusted net tangible book value per share after this offering and the assumed combined public offering price per share.
Investors will pay $0.51 per share but the as adjusted net tangible book value is $0.02 lower, resulting in immediate dilution. This is a direct financial impact on new investors.
Added in current filing · verify on EDGAR →
At the Company’s planned Special Meeting of Stockholders, to be held August 14, 2026, the Company’s stockholders are being asked to approve a proposal to grant the Board discretionary authority to amend our amended and restated certification of incorporation to effect a reverse stock split of all of our issued and outstanding shares of common stock at a ratio of not less than 1-for-5 and not greater than 1-for-50 (the “Reverse Stock Split”), such ratio to be determined by our Board of at any time within twelve months from the date that stockholder approval is obtained, without further approval or authorization of our stockholders, with the exact ratio to be determined by the Board without further approval or authorization of our stockholders.
The company plans a reverse stock split to maintain Nasdaq listing, but there is no assurance it will be approved or that the stock price will remain high enough. This could reduce liquidity and increase costs for odd-lot holders.
Added in current filing · verify on EDGAR →
Holders of the Pre-Funded Warrants may exercise their right to acquire the common stock and pay an exercise price of $0.0001 per share and holders of the Common Warrants may acquire shares of common stock issuable upon exercise of such warrants at an assumed exercise price of $0.51 per share. The Pre-Funded Warrants do not expire and the Common Warrants will expire five years from the date of issuance.
The offering includes pre-funded warrants with a nominal exercise price and common warrants with a $0.51 exercise price. There is no established trading market for these warrants, limiting liquidity.
Business · Business
Valion Bio pivoted from bioelectronic devices to a biopharma focused on Entolimod, a TLR5 agonist for ARS and oncology, and launched a CDMO subsidiary.
Added in current filing · verify on EDGAR →
During fiscal year 2025, Valion executed a deliberate and material strategic transformation: pivoting from a diversified bioelectronic medical device company to a focused biopharmaceutical company built around the TLR5 agonist franchise.
The company completely changed its business model in 2025, abandoning its prior bioelectronic device focus to concentrate on a single drug candidate. This is a fundamental shift that investors need to understand, as the company's future now depends almost entirely on Entolimod's success.
Added in current filing · verify on EDGAR →
A cornerstone of this transition was the execution of an exclusive worldwide licensing agreement with Statera Biopharma, Inc. This agreement added Entolimod™, a late-stage Toll-like Receptor 5 (TLR5) agonist, to our clinical pipeline.
Valion acquired the rights to its lead drug candidate through a licensing deal with Statera Biopharma. The terms of this agreement, including any upfront payments, milestones, or royalties, are not disclosed in this section, but the exclusive worldwide license is the foundation of the company's new business.
Added in current filing · verify on EDGAR →
These assets represent a high-value investment opportunity, having been the subject of over 40 clinical and preclinical trials supported by $140 million in prior capital, including $35.6 million in non-dilutive funding from the Department of Defense (DoD), DTRA, NASA, and the NIH.
The company highlights that Entolimod has already received substantial prior investment, including significant government funding. This is presented as validation of the asset's potential, but investors should note that this is the company's characterization and does not guarantee future success.
Added in current filing · verify on EDGAR →
The FDA has recognized the clinical importance of Entolimod by granting it Fast Track and Orphan Drug designations for the prevention and treatment of Acute Radiation Syndrome (ARS).
Entolimod has received Fast Track and Orphan Drug designations from the FDA for ARS. These designations can provide benefits such as expedited review and market exclusivity, but they do not guarantee approval.
Added in current filing · verify on EDGAR →
In December 2025, the Company launched Velocity Bioworks, Inc., a wholly owned subsidiary operating as a CDMO. Velocity serves a dual strategic purpose: it de-risks our Entolimod commercialization plan by providing internal control over the manufacturing and validation timeline, and it creates a new vertical revenue by offering specialized services to external partners.
Valion created a contract development and manufacturing organization (CDMO) subsidiary to handle manufacturing for Entolimod and potentially generate revenue from third-party customers. This is a significant operational expansion that adds complexity and capital requirements, but the company frames it as a way to reduce risk and diversify revenue.
Experts · Experts
Auditor's report includes a going concern explanatory paragraph; no expert conflicts disclosed.
Added in current filing · verify on EDGAR →
which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern
The independent auditor's report on the financial statements includes an explanatory paragraph stating that conditions raise substantial doubt about the company's ability to continue as a going concern. This is a significant risk factor for investors.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify